Interpace Diagnostics Group, Inc. (IDXG) EPS Estimated At $-0.08

July 14, 2018 - By Benjamin Allen

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Logo

Analysts expect Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) to report $-0.08 EPS on August, 9.They anticipate $0.57 EPS change or 87.69 % from last quarter’s $-0.65 EPS. After having $-0.11 EPS previously, Interpace Diagnostics Group, Inc.’s analysts see -27.27 % EPS growth. The stock increased 2.81% or $0.026 during the last trading session, reaching $0.946. About 496,520 shares traded or 82.52% up from the average. Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) has declined 55.08% since July 14, 2017 and is downtrending. It has underperformed by 67.65% the S&P500.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company has market cap of $26.36 million. The firm offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. It currently has negative earnings. The Company’s clients consist primarily of physicians, hospitals, and clinics.

More news for Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) were recently published by: Benzinga.com, which released: “Benzinga’s Top Upgrades, Downgrades For June 22, 2018” on June 22, 2018. Streetinsider.com‘s article titled: “Ladenburg Thalmann Starts Interpace Diagnostics Group Inc (IDXG ) at Buy” and published on June 22, 2018 is yet another important article.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.